Bank of Hawaii Sells 1,335 Shares of AstraZeneca PLC (NASDAQ:AZN)

Bank of Hawaii lowered its position in AstraZeneca PLC (NASDAQ:AZN) by 12.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,088 shares of the company’s stock after selling 1,335 shares during the period. Bank of Hawaii’s holdings in AstraZeneca were worth $708,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. McClarren Financial Advisors Inc. raised its position in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares during the period. GHP Investment Advisors Inc. bought a new position in AstraZeneca in the 2nd quarter worth $26,000. Capital Performance Advisors LLP bought a new position in AstraZeneca in the 3rd quarter worth $28,000. Pathway Financial Advisers LLC purchased a new position in AstraZeneca during the first quarter valued at $29,000. Finally, CANADA LIFE ASSURANCE Co grew its holdings in AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after purchasing an additional 146 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of NASDAQ AZN opened at $66.40 on Tuesday. The company has a market cap of $205.88 billion, a P/E ratio of 31.77, a P/E/G ratio of 1.20 and a beta of 0.47. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The firm’s fifty day moving average is $73.19 and its two-hundred day moving average is $77.72.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the previous year, the firm posted $0.87 earnings per share. The business’s revenue was up 18.0% compared to the same quarter last year. As a group, analysts anticipate that AstraZeneca PLC will post 4.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on AZN shares. TD Cowen boosted their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Finally, Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and an average target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.